Spine submission from Medtronic
This article was originally published in The Gray Sheet
PMA submission for rhBMP-2 bone growth stimulator in posterior lumbar spinal fusion is announced Sept. 29 at the North American Spine Society meeting in Philadelphia. The recombinant bone morphogenetic protein - to be delivered via the Amplify matrix - is the active component in Medtronic's InFuse bone graft for tibia fractures, which entered the U.S. market in May 2004 (1"The Gray Sheet" May 17, 2004, p. 3). The PMA is supported by a randomized, prospective clinical study that enrolled more than 460 participants, Medtronic says...
You may also be interested in...
Medtronic will attempt to persuade CMS that the firm's Kinetra deep-brain stimulation device marks a substantial clinical improvement over its predecessor - the dual-implant Soletra - and therefore qualifies for a new technology "add-on" payment
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.